Pediatric acute myeloid leukemia patients with KMT2A rearrangements: a single-center retrospective study

Figures & data

Table 1. Main characteristics of the 21 AML pediatric patients with t (v; 11q23)/KMT2A rearrangents.

	Full matched HSCT (n = 4)	Haploidentical HSCT (n = 17)	P
Male gender, n (%)	3 (75.00%)	12 (70.59%)	1.000
Age, years	4.65 ± 4.23	6.06 ± 4.59	0.583
WBC (×10^9/L)	5.47 ± 3.03	49.75 ± 54.64	0.004
HGB (g/L)	83.75 ± 12.97	98.53 ± 23.09	0.221
PLT (×10^9/L)	178.00 ± 155.33	109.18 ± 65.85	0.168
CNS involvement			1.000
Yes	0	2
No	4	15
Extramedullary invasion			1.000
Yes	1	4
No	3	13
Leukocyte implantation time			0.586
≥ 12d	1	9
< 12d	3	8
Platelet implantation time			1.000
≥ 12d	3	11
< 12d	1	6
acute GVHD (Grade I–IV)			0.021
≤I	4	4
II–IV	0	13
Chronic GVHD			0.272
Yes	1	11
No	3	6
Prognosis			0.546
Death	0	4
Alive	4	13

Notes: WBC: white blood cell; HGB: hemoglobin; PLT: platelets; CNS; central nervous system; GVHD: graft-versus-host disease.

Figure 1. The differences of the EFS, OS and CIR rates between the high-risk group and the medium-risk group were shown (P = 0.428, P = 0.398, P = 0.428).

Figure 2. The differences in EFS, OS and CIR rates of children with full matched HSCT and haplo-HSCT were shown (P = 0.303, P = 0.289, P = 0.303).

Figure 3. The differences in EFS, OS of children with KMT2A/MLLT3, KMT2A/MLLT10 and Others were shown (P = 0.373, P = 0.464).